Table 2.
Lifetime prevalence of substance use and other psychiatric disorders among MDMA+ (n = 21) and MDMA− (n = 21)
| SCID-IV diagnosis | Lifetime prevalence rate
|
||
|---|---|---|---|
| MDMA+% (n) | MDMA−% (n) | 2-Tailed p value | |
| Substance use | |||
| Alcohol abuse | 38% (8) | 24% (5) | NS |
| Alcohol dependence (>1 year ago) | 0% (0) | 5% (1) | NS |
| Cannabis abuse | 9% (2) | 19% (4) | NS |
| Cannabis dependence | 19% (4) | 5% (1) | NS |
| Cocaine abuse | 5% (1) | 0% (0) | NS |
| Cocaine dependence* | 5% (1) | 0% (0) | NS |
| Amphetamine abuse | 5% (1) | 0% (0) | NS |
| Amphetamine dependence | 0% (0) | 0% (0) | — |
| Opioid abuse | 0% (0) | 0% (0) | — |
| Opioid dependence | 0% (0) | 0% (0) | — |
| Sedative abuse | 5% (1) | 0% (0) | NS |
| Sedative dependence | 0% (0) | 0% (0) | — |
| Hallucinogen abuse | 9% (2) | 0% (0) | NS |
| Hallucinogen dependence | 5% (1) | 0% (0) | NS |
| Polysubstance abuse | 0% (0) | 0% (0) | — |
| Polysubstance dependence | 0% (0) | 0% (0) | — |
| Other psychiatric | |||
| Beck Depression Inventory, median (IQR) | 3 (0, 15) | 3 (1, 7) | NS |
| Major depressive disorder | 29% (6) | 14% (3) | NS |
| Bipolar disorder | 0% (0) | 0% (0) | — |
| Antisocial personality disorder | 0% (0) | 0% (0) | — |
NS = Not significant (p ≥ .05).
*
Note. One participant in the MDMA+ group met criteria for cocaine dependence 2 years before assessment in the current study as a result of light (two lines per day) use over a 3-month period.